Pharmacokinetics and pharmacodynamics of the DPP-4 inhibitor, LAF237, in patients with type diabetes.

被引：0
|
作者：
He, YL [1 ]
Balch, A [1 ]
Campestrini, J [1 ]
Rivere, GJ [1 ]
Serra, D [1 ]
Prasad, P [1 ]
Ligueros-Saylan, M [1 ]
机构：
[1] Novartis Pharmaceut, NIBR, Cambridge, MA USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2005年 / 77卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：P56 / P56
页数：1
相关论文
共 50 条
  • [1] The pharmacokinetics and DPP-4 inhibition of LAF237 in healthy volunteers
    He, YL
    Barilla, D
    Ligueros-Saylan, M
    Rivierc, GJ
    Campestrini, J
    Pratapa, P
    JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (10): : 1212 - 1212
  • [2] Pharmacokinetics and pharmacodynamics of the DPP-4 inhibitor, vildagliptin, in Japanese patients with type 2 diabetes.
    Hayashi, N.
    Karube, M.
    Kumagai, Y.
    Fujita, Y.
    Irie, S.
    Ikeda, Y.
    He, Y. L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 : S68 - S68
  • [3] Long-term efficacy of the DPP-4 inhibitor, LAF237, in patients with type 2 diabetes inadequately treated with metformin
    Pratley, RE
    Gomis, R
    Standl, E
    Schweizer, A
    Mills, D
    Ahren, B
    DIABETOLOGIA, 2004, 47 : A69 - A70
  • [4] LAF237 is a DPP-4 inhibitor that improves model-assessed β-cell function in drug-naive patients with Type 2 diabetes
    Mari, A
    Sallas, WM
    He, YL
    Watson, C
    Ligueros-Saylan, M
    Foley, JE
    DIABETOLOGIA, 2004, 47 : A284 - A285
  • [5] The DPP-4 inhibitor, LAF237, improves glycemic control in patients with type 2 diabetes (T2DM) inadequately treated with metformin
    Ahren, B
    Gomis, R
    Mills, D
    Schweizer, A
    DIABETES, 2004, 53 : A83 - A83
  • [6] Combination of the DPP-4 inhibitor vildagliptin (LAF237) with pioglitazone is safe and well tolerated with no pharmacokinetic interaction
    Serra, DB
    He, YL
    Wang, Y
    Riviere, G
    Bullock, J
    Schwartz, S
    Ligueros-Saylan, M
    DIABETES, 2005, 54 : A528 - A528
  • [7] Twelve-week monotherapy with the DPP-4 inhibitor, LAF237 improves glycemic control in patients with type 2 diabetes (T2DM)
    Pratley, R
    Galbreath, E
    DIABETES, 2004, 53 : A83 - A83
  • [8] Lack of effect of LAF237 on C-peptide clearance in patients with type 2 diabetes.
    He, YL
    Horowitz, A
    Watson, C
    Foley, J
    Sallas, W
    Ligueros-Saylan, M
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P56 - P56
  • [9] Pharmacokinetics and Pharmacodynamics of KR-66223, a Novel DPP-4 Inhibitor
    Song, Jin Sook
    Lee, Kyeong-Ryoon
    Kwon, Hyun Jin
    Dal Rhee, Sang
    Kim, Min Sun
    Choi, Sung Hum
    Lee, Sung-Hack
    Song, Im Sook
    Ahn, Jin Hee
    Ahn, Sung Hoon
    Bae, Myung Ae
    DRUG METABOLISM AND PHARMACOKINETICS, 2012, 27 (02) : 216 - 222
  • [10] No pharmacokinetic interactions or acute clinical safety issues preclude combination of the DPP4 inhibitor LAF237 with glyburide
    Barilla, D
    He, YL
    Balez, S
    Bullock, J
    Ho, YY
    Guiterrez, M
    Ligueros-Saylan, M
    DIABETES, 2004, 53 : A470 - A470
12345